Outcomes of Second-Line Treatment By Dasatinib in Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia Patients with and without Comorbidities

MLA

Ionova, Tatyana, et al. “Outcomes of Second-Line Treatment By Dasatinib in Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia Patients with and without Comorbidities.” Blood, vol. 126, no. 23, Dec. 2015, p. 5147. EBSCOhost, https://doi.org/10.1182/blood.V126.23.5147.5147.

APA

Ionova, T., Nikitina, T., Kuchma, G., Lomaia, E., Shnaider, T., Usacheva, E., & Kurbatova, K. (2015). Outcomes of Second-Line Treatment By Dasatinib in Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia Patients with and without Comorbidities. Blood, 126(23), 5147. https://doi.org/10.1182/blood.V126.23.5147.5147

Chicago

Ionova, Tatyana, Tatyana Nikitina, Galina Kuchma, Elza Lomaia, Tatyana Shnaider, Elena Usacheva, and Kira Kurbatova. 2015. “Outcomes of Second-Line Treatment By Dasatinib in Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia Patients with and without Comorbidities.” Blood 126 (23): 5147. doi:10.1182/blood.V126.23.5147.5147.